Bringing Evo Devo to Life

Sean Carroll's book shows how the central black box of development that maps phenotypes onto genotypes is revealing its secrets in many exquisite, and frequently unexpected, ways

Low-dimensional hybrid perovskites containing an organic cation with an extended conjugated system : tuning the excitonic absorption features

Low-dimensional hybrid perovskites are receiving increased attention. One of the advantages of the low-dimensional hybrids over their 3D counterparts is their greater structural flexibility towards the incorporation of bigger, more complex, organic cations. In this communication, we introduce a pyrene derivative as an organic cation containing an extended pi-system for use in a variety of low-dimensional hybrids. We show that materials with different excitonic absorption features can be obtained by tuning the iodide/lead ratio in the precursor solutions, using the same pyrene cation. In this way, hybrids with optical characteristics corresponding to 2D, 1D and 0D hybrid perovskites are obtained. The formation and thermal stability of the different hybrids is analysed and compared

Treatment of symptoms of the menopause: an endocrine society clinical practice guideline

Objective: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures